Dutasteride for reducing the risk of developing prostate cancer in men who are considered to be at increased risk of developing the disease
Please note that following on from information provided to NICE by the company in March 2011, the appraisal of Dutasteride for reducing the risk of prostate cancer [ID75] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 75
Referral date 01 March 2009
Topic area
  • Cancer
  • Urogenital

Provisional Schedule

Closing date for invited submissions / evidence submission: 18 January 2011
1st appraisal committee meeting: 01 January 2100

Project Team

Communications manager: Alice Law
Executive Lead: Peter Littlejohns
Project manager: Lori Farrar
Technical Lead: Panagiota Vrouchou

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
20 January 2023 Discontinued. Please note that following on from information provided to NICE by the company in March 2011, the appraisal of Dutasteride for reducing the risk of prostate cancer [ID75] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
27 April 2011

NICE has been informed by the manufacturer of dutasteride, GSK, that they have withdrawn their licensing application for the above indication. Therefore this appraisal topic has been suspended and the appraisal committee agenda topic that was due to take place on 14 September 2011 has been cancelled.

NICE will continue to monitor any development and update this webpage if the situation changes.
21 January 2011

NICE has re-scheduled the first Appraisal Committee meeting for a number of technology appraisal topics.

In rescheduling these topics we have been careful to maintain our ability to issue timely recommendations.

This appraisal of Dutasteride for reducing the risk of developing prostate cancer is one of the topics that has been identified.

The first appraisal committee discussion will now take place on 14 September 2011. The second committee meeting (if required) will also be rescheduled.
30 July 2010

Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin end of October 2010. The deadline for submissions is expectedin approximately mid January 2011.

For further information on our processes and methods, please see our CHTE processes and methods manual